Melanoma: Complete response to anti-PD-1s 'generally durable'

But the results of retreating relapsed patients are disappointing, say researchers

Three years after starting anti-PD-1 therapy, most patients who have complete response maintain that status despite stopping their treatment.

Intravenous infusion

A real-world study of US patients with advanced melanoma shows that complete response can be maintained for 21 months without further anti-PD-1 therapy but reveals “disappointing” results for patients who relapse and are retreated.

The analysis of data from 396 patients with unresectable stage III or stage IV melanoma, at